Prolia is the first monoclonal antibody used in osteoporosis treatment. It reduces risk of vertebras and other fractures, and prevents bone complications. Prolia is usually taken by females after menopause. Males take Prolia to reduce bone mass loss related to hormone ablation concurrent prostate cancer treatment.
Prolia is dosed via subcutaneous injections. It contains active substance called Denosumab. It is recommended that all patients receiving Denosumab should also take calcium and vitamin D.
It has high effectiveness in respect of bone fraction prevention and bone rebuilt processes.
The treatment shall be repeated every 6 months, however dosing and time of treatment is determined individually.